Claims for Patent: 6,992,102

Summary for Patent: 6,992,102

Title:	Bicyclic modulators of androgen receptor function
Abstract:	The invention provides compounds of the formula I ##STR00001## wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia, and also provided are pharmaceutical compositions containing such compounds.
Inventor(s):	Hamann; Lawrence (Cherry Hill, NJ), Augeri; David (Princeton, NJ), Sun; Chongqing (East Windsor, NJ), Robl; Jeffrey A. (Newtown, PA), Salvati; Mark E. (Lawrenceville, NJ), Wang; Tammy (Lawrenceville, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	10/685,020
Patent Claims:	1. A compound of the formula Ia ##STR00089## wherein R.sub.1 is selected from the group consisting of hydrogen (H), cyano (--CN), nitro (--NO.sub.2), halo, OR.sub.4, CO.sub.2R.sub.5, CONHR.sub.5, COR.sub.5, S(O).sub.mR.sub.5, SO.sub.2NR.sub.5R.sub.5', NHCOR.sub.5 and NHSO.sub.2R.sub.5; R.sub.2 is selected from the group consisting of hydrogen (H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, arylalkyl or substituted arylalkyl, CO.sub.2R.sub.5, CONR.sub.5R.sub.5' and CH.sub.2OR.sub.5; R.sub.3 is selected from the group consisting of hydrogen (H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, halo, cyano(--CN), NHCOR.sub.5, NHCO.sub.2R.sub.5, NHCONR.sub.5R.sub.5', NHSO.sub.2R.sub.5 and OR.sub.4; R.sub.4 in each functional group is independently selected from the group consisting of hydrogen (H), alkyl or substituted alkyl, CHF.sub.2, CF.sub.3 and COR.sub.5; R.sub.5 and R.sub.5' in each functional group are each independently selected from the group consisting of hydrogen(H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, and --CN; W is selected from the group consisting of (CR.sub.6R.sub.6').sub.m, CHOH(CR.sub.6R.sub.6').sub.m, CO(CR.sub.6R.sub.6').sub.m and C.dbd.NOR.sub.4(CR.sub.6R.sub.6').sub.m; R.sub.6 and R.sub.6' are each independently selected from the group consisting of hydrogen (H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, halo, cyano (--CN), NHCOR.sub.5, NHCO.sub.2R.sub.5, NHCONR.sub.5R.sub.5', NHSO.sub.2R.sub.5 and OR.sub.4; X is selected from the group consisting of methylene (--CH.sub.2--); Y is selected from the group consisting of oxygen(O), sulfur(S) and hydrogen (H.sub.2); Z is selected from the group consisting of oxygen(O), sulfur(S), NH and NR.sub.5; A and B are each independently selected from the group consisting of hydrogen (H), halo, cyano(--CN), nitro(--NO.sub.2), alkyl or substituted alkyl and OR.sub.4; and m is an integer from 0 to 2; or prodrug esters, pharmaceutically acceptable salts and stereoisomers thereof. 2. A pharmaceutical composition comprising a compound as defined in claim 1. 3. The pharmaceutical composition of claim 2 further comprising at least one additional therapeutic agent selected from the group consisting of parathyroid hormone, bisphosphonates, estrogen, testosterone, progesterone, growth hormone and anti-anxiety agents selected from the group consisting of diazepan, lorazepam, buspirone, oxazepam and hydroxyzine pamoate.

Details for Patent 6,992,102

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2021-07-31